World's Best Scientists 2026 revealed!
Atsushi Ohtsu

Atsushi Ohtsu

D-Index & Metrics

Medicine

D-Index
103
Citations
52531
World Ranking
7221
National Ranking
171

Atsushi Ohtsu publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Atsushi Ohtsu sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 723 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Atsushi Ohtsu D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Atsushi Ohtsu sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Atsushi Ohtsu is affiliated with Juntendo University in Japan and has a significant body of research primarily focused on medicine, with extensive contributions in oncology. Their work spans multiple subfields including oncology, pulmonary and respiratory medicine, cancer research, pathology and forensic medicine, and surgery.

The scientist's research topics cover a range of areas related to cancer, notably colorectal and gastric cancers. Key topics include colorectal cancer treatments and studies, gastric cancer management and outcomes, genetic factors in colorectal cancer, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, esophageal cancer research and treatment, and cancer treatment and pharmacology.

Ohtsu has published research in numerous academic journals. The most frequent venues for their publications are the Journal of Clinical Oncology, Annals of Oncology, ESMO Open, Cancer Science, and Nature Medicine.

Some of the recent papers associated with Ohtsu include:

  • Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies, 2020, Nature Medicine
  • Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial, 2021, Nature Medicine
  • Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial, 2021, Gastric Cancer
  • Therapeutic landscape and future direction of metastatic colorectal cancer, 2023, Nature Reviews Gastroenterology & Hepatology
  • Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer, 2021, Annals of Oncology

Ohtsu frequently collaborates with other researchers in the oncology field. Notable co-authors include Takayuki Yoshino, Hideaki Bando, Tomohiro Nishina, Kei Muro, and Hiroya Taniguchi.

Best Publications

  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

    Yung Jue Bang;Eric Van Cutsem;Andrea Feyereislova;Hyun C. Chung

  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang Cheul Oh

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Robert J Mayer;Eric Van Cutsem;Alfredo Falcone;Takayuki Yoshino

  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

    Atsushi Ohtsu;Manish A. Shah;Eric Van Cutsem;Sun Young Rha

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patients

    Y Sakata;A Ohtsu;N Horikoshi;K Sugimachi

  • Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

    Narikazu Boku;Seiichiro Yamamoto;Haruhiko Fukuda;Kuniaki Shirao

  • Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study

    Taroh Satoh;Rui-Hua Xu;Hyun Cheol Chung;Guo-Ping Sun

  • Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)

    Atsushi Ohtsu;Yasuhiro Shimada;Kuniaki Shirao;Narikazu Boku

  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

    Eric Van Cutsem;Sanne de Haas;Yoon-Koo Kang;Atsushi Ohtsu

  • Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study

    Atsushi Ohtsu;Jaffer A. Ajani;Yu Xian Bai;Yung Jue Bang

  • Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

    Peter C. Thuss-Patience;Manish A. Shah;Atsushi Ohtsu;Eric Van Cutsem

  • Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus

    Atsushi Ohtsu;Narikazu Boku;Kei Muro;Keisho Chin

  • Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus

    Satoshi Ishikura;Keiji Nihei;Atsushi Ohtsu;Narikazu Boku

  • Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.

    Josep Tabernero;Paulo M. Hoff;Lin Shen;Atsushi Ohtsu

  • Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

    Toshihiro Kudo;Yasuo Hamamoto;Ken Kato;Takashi Ura

  • TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

    Takayuki Yoshino;Nobuyuki Mizunuma;Kentaro Yamazaki;Tomohiro Nishina

  • Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer

    Narikazu Boku;Atsushi Ohtsu;Yasuhiro Shimada;Kuniaki Shirao

  • Bevacizumab in Combination With Chemotherapy as First-LineTherapyinAdvancedGastricCancer:ABiomarker EvaluationFromtheAVAGASTRandomizedPhaseIIITrial

    Eric Van Cutsem;Sanne de Haas;Yoon-Koo Kang;Atsushi Ohtsu

Frequent Co-Authors

Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Toshihiko Doi
Toshihiko Doi Okayama University
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine
Kei Muro
Kei Muro National Cancer Research Institute, UK
Kohei Shitara
Kohei Shitara Yahoo (United Kingdom)
Atsushi Ochiai
Atsushi Ochiai University of Tokyo
Teruhiko Yoshida
Teruhiko Yoshida National Cancer Research Institute, UK
Jun-ichi Sawada
Jun-ichi Sawada University of Shizuoka
Nagahiro Saijo
Nagahiro Saijo AstraZeneca (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to numerous health-related careers beyond the traditional MD. For those interested in healthcare management, pursuing one of the cheapest mha programs online can provide a fast track to administration roles. Such programs are ideal for students seeking leadership positions in hospitals and medical organizations.

Nurses aiming to advance may consider one of the most affordable online dnp programs. Achieving a Doctorate in Nursing Practice enables higher clinical or executive opportunities while maintaining flexibility for working professionals.

For those drawn to pharmaceuticals, enrolling in an online pharmd program can lead to careers as licensed pharmacists. Many programs offer online coursework, allowing students to balance study with personal commitments.

Additionally, demand is growing in digital health information. Accredited online schools for health information management are equipping students for essential roles in medical data, privacy, and IT infrastructure.

Each of these online pathways offers flexibility and can complement or offer alternatives to traditional medical education. Explore which option aligns with your career goals and lifestyle.

Best Scientists Citing Atsushi Ohtsu

Trending Scientists

Recently Published Articles